Document is current

Article History

Received: 27 September 2024

Accepted: 12 February 2025

First Online: 12 March 2025

Declarations

:

: Not applicable.

: Not applicable.

: AF: Andrea Fagiolini is/has been a consultant and/or a speaker and/or has received research grants from Angelini, Boehringer Ingelheim, Idorsia, Italfarmaco, Lundbeck, Janssen, Medicamenta, Mylan, Otsuka, Pfizer, Recordati, Rovi, Sunovion, Teva, Viatris.J.A.R.Q. was on the speakers’ bureau and/or acted as a consultant for Biogen, Idorsia, Casen-Recordati, Janssen-Cilag, Novartis, Takeda, Bial, Sincrolab, Neuraxpharm, Novartis, BMS, Medice, Rubió, Uriach, Technofarma, and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for attending psychiatric meetings from Idorsia, Janssen-Cilag, Rubió, Takeda, Bial, and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Exeltis, Idorsia, Janssen-Cilag, Neuraxpharm, Oryzon, Roche, Probitas, and Rubió.PS: Paul Seerden is/ has been a consultant and/ or speaker from Janssen-Cilag, Recordati and Lundbeck in the last 3 yearsCVO: no conflict of interest.ALM: ALM has received consultancy fees or honoraria/research grants in the last 5 years from Boehringer Ingelheim, Casen Recordati, Eli Lilly, Forum Pharmaceuticals, Instituto de Salud Carlos III, Janssen Cilag, Lundbeck, Otsuka, Pfizer, Roche, ROVI, Servier, and the Junta de Castilla y León.J.A.R.Q. was on the speakers’ bureau and/or acted as a consultant for Biogen, Idorsia, Casen-Recordati, Janssen-Cilag, Novartis, Takeda, Bial, Sincrolab, Neuraxpharm, Novartis, BMS, Medice, Rubió, Uriach, Technofarma, and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for attending psychiatric meetings from Idorsia, Janssen-Cilag, Rubió, Takeda, Bial, and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Exeltis, Idorsia, Janssen-Cilag, Neuraxpharm, Oryzon, Roche, Probitas, and Rubió.PS: Paul Seerden is/ has been a consultant and/ or speaker from Janssen-Cilag, Recordati and Lundbeck in the last 3 years.CVO: no conflict of interest.ALM: ALM has received consultancy fees or honoraria/research grants in the last 5 years from Boehringer Ingelheim, Casen Recordati, Eli Lilly, Forum Pharmaceuticals, Instituto de Salud Carlos III, Janssen Cilag, Lundbeck, Otsuka, Pfizer, Roche, ROVI, Servier, and the Junta de Castilla y León.